1. Introduction {#sec1}
===============

As of 2012, more than 4.8 million Americans were prescribed stimulant medications to treat attention deficit hyperactivity disorder (ADHD) \[[@B1]\]. One out of ten Americans above the age of 12 are prescribed antidepressants, selective serotonin reuptake inhibitors (SSRIs) being the most common \[[@B2]\]. Central nervous system- (CNS-) stimulant ADHD medications have been associated with side effects such as bruxism \[[@B3]\] that can possibly cause TMD-like symptoms \[[@B4]\]. With the increasing use of stimulant ADHD medications, it is important to see if there is a relationship between these prescribed medications and TMD symptoms \[[@B5]\].

TMD can manifest in a variety of symptoms including pain or tenderness in the face muscles or jaw joint, a limited range of motion of the jaw, popping and clicking of the jaw, and headaches \[[@B6]\]. In addition to the adverse symptoms of TMD, treatment can often be extensive as well as expensive.

TMD symptoms are also more commonly seen in the female population. Of concern could be the recent increase in use of stimulant ADHD medications in women aged 26 to 34 \[[@B1]\]. The inherent predisposition to TMD symptoms in women combined with an increased use of ADHD medications could possibly put this patient population at an increased risk for developing TMD symptoms. Given this information, we hypothesize that there is an association between ADHD medications, as well as SSRIs, and the frequency of reported TMD symptoms.

2. Subjects and Methods {#sec2}
=======================

All subjects in this study were participants in the Dental Registry and DNA Repository of the University of Pittsburgh School of Dental Medicine \[[@B7]--[@B9]\]. All participants sought treatment at the University of Pittsburgh School of Dental Medicine dating back to September 2006. In April 2015, data from 4,959 individuals were queried from the registry and repository for this study and 469 individuals taking ADHD and SSRI medications were selected for this study. The records of these individuals were evaluated to determine if they had any TMD symptoms (pain or discomfort, cracking or clicking when opening the mouth).

Chi-square tests were used to determine associations between being prescribed any stimulant ADHD or SSRI medications and TMD symptoms. The same was performed for subjects prescribed any SSRI medication in search of a significant association between SSRIs and TMD symptoms. We used the likelihood ratio for comparisons when we violated the assumption of minimum expected cell count to be used for Pearson\'s chi-square. Alpha was established at 5%.

Standardized residuals were then compared to determine which medication in each category was responsible for a significantly different report rate of TMD symptoms.

3. Results {#sec3}
==========

The mean age of the 469 participants was 46 years, with 38% of participants identifying as male (*N* = 179) and 62% female (*N* = 290). Furthermore, the majority of participants were White (*N* = 394; 84%). The remaining 16% were comprised of Black individuals (*N* = 52), Hispanics (*N* = 6), and other groups (*N* = 17).

There was a trend, albeit not statistically significant, for being prescribed ADHD medication and reporting TMD symptoms (*p* = 0.065). Likewise, there was no significant association between taking SSRIs and reporting TMD symptoms (*p* = 0.12). We found differences in occurrence of reported TMD symptoms between the different ADHD stimulant medications (*p* = 0.04, six degrees of freedom). The likelihood ratio of .010 suggested that there is at least one medication that is statistically significant among the others in regard to reported TMD symptoms. Further testing by means of finding the expected counts and adjusted residuals for each ADHD medication determined that Concerta was the statistically significant medication when compared to the others ([Table 1](#tab1){ref-type="table"}). Additionally, taking the observed counts versus the expected counts in [Table 1](#tab1){ref-type="table"} into consideration also depicts that subjects prescribed Concerta are less likely to report TMD symptoms than subjects prescribed any other ADHD stimulant. There were no differences based on sex or ethnic background (data not shown).

Similarly, the group of SSRIs also showed that there is a medication with a significant difference in regard to reported TMD symptoms (*p* = 0.075, 10 degrees of freedom); thus the likelihood ratio is of .040. Celexa showed a difference in expected reporting of TMD symptoms when compared to the other SSRIs ([Table 2](#tab2){ref-type="table"}). Additionally, taking the observed counts versus the expected counts in [Table 2](#tab2){ref-type="table"} into consideration also depicts that subjects prescribed Celexa are more likely to report TMD symptoms than subjects prescribed any other SSRI. There were no differences based on sex or ethnic background (data not shown).

Being prescribed both an ADHD medication and SSRI showed a trend, albeit not statistically significant, for reporting TMD symptoms (*p* = 0.074).

4. Discussion {#sec4}
=============

The results show that there is no formal significant difference in TMD symptoms between those that are prescribed ADHD medications and those that are not prescribed ADHD medications. This same statement also holds true for subjects prescribed SSRIs and those not prescribed SSRIs. However, there does seem to be a significant difference*between* the different medications prescribed. Our data shows that subjects prescribed Concerta for ADHD are less likely to report TMD symptoms when compared to subjects taking other ADHD medications. It is also important to consider that our data shows that subjects taking the SSRI Celexa are more likely to report experiencing TMD symptoms than those prescribed an SSRI other than Celexa.

This could be clinically important when treating patients who are already at an increased risk for TMD. According to numerous studies, including the National Institute of Dental and Craniofacial Research, women are at higher risk than are men for developing TMD symptoms \[[@B6]\]. Since TMD is a multifactorial disorder \[[@B10]\], it may be wise to limit the number of contributing factors targeted for intervention. For example, a patient that is already predisposed to TMD may benefit from being prescribed Concerta versus other ADHD stimulants due to Concerta\'s lower frequency of reported TMD symptoms. Similarly, the same patient population that requires a SSRI prescription may benefit from a SSRI other than Celexa. Understanding better the contributing factors to this multifactorial disorder could prove beneficial to the patient\'s health and ultimately their quality of life.

In summary, we report here for the first time that specific ADNH and SSRI drugs may impact risks for developing TMD.
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###### 

Comparison of the type of ADHD medication by the presence of TMD symptoms. The results show that Concerta is the ADHD medication that is significantly different compared to the rest.

                                 TMD diagnosis   Total   
  ------------------------------ --------------- ------- --------
  *Type of ADHD medication*                               
  None                                                    
   Count                         237             171     408
   Expected count                243.6           164.4   408.0
   % within type of medication   58.1%           41.9%   100.0%
   Adjusted residual             −1.8            1.8      
  Adderall                                                
   Count                         13              13      26
   Expected count                15.5            10.5    26.0
   % within type of medication   50.0%           50.0%   100.0%
   Adjusted residual             −1.0            1.0      
  Concerta                                                
   Count                         14              1       15
   Expected count                9.0             6.0     15.0
   % within type of medication   93.3%           6.7%    100.0%
   Adjusted residual             **2.7**         −2.7     
  Ritalin                                                 
   Count                         11              4       15
   Expected count                9.0             6.0     15.0
   % within type of medication   73.3%           26.7%   100.0%
   Adjusted residual             1.1             −1.1     
  Vyvanse                                                 
   Count                         3               0       3
   Expected count                1.8             1.2     3.0
   % within type of medication   100.0%          0.0%    100.0%
   Adjusted residual             1.4             −1.4     
  Adderall and Vyvanse                                    
   Count                         1               0       1
   Expected count                .6              .4      1.0
   % within type of medication   100.0%          0.0%    100.0%
   Adjusted residual             .8              −.8      
  Concerta and Ritalin                                    
   Count                         1               0       1
   Expected count                .6              .4      1.0
   % within type of medication   100.0%          0.0%    100.0%
   Adjusted residual             .8              −.8      
                                                         
  Total                                                   
   Count                         280             189     469
   Expected count                280.0           189.0   469.0
   % within type of medication   59.7%           40.3%   100.0%

Bold highlights the highest adjusted residual.

###### 

Comparison of the type of SSRI medication by the presence of TMD symptoms. The results show that Celexa is the SSRI that is significantly different compared to the rest.

                           TMD diagnosis   Total     
  ------------------------ --------------- --------- --------
  *Type of SSRI*                                      
  None                                                
   Count                   80              42        122
   Expected count          72.8            49.2      122.0
   % within type of SSRI   65.6%           34.4%     100.0%
   Adjusted residual       1.5             −1.5       
  Celexa                                              
   Count                   30              35        65
   Expected count          38.8            26.2      65.0
   % within type of SSRI   46.2%           53.8%     100.0%
   Adjusted residual       −2.4            **2.4**    
  Lexapro                                             
   Count                   40              30        70
   Expected count          41.8            28.2      70.0
   % within type of SSRI   57.1%           42.9%     100.0%
   Adjusted residual       −.5             .5         
  Prozac                                              
   Count                   58              27        85
   Expected count          50.7            34.3      85.0
   % within type of SSRI   68.2%           31.8%     100.0%
   Adjusted residual       1.8             −1.8       
  Luvox                                               
   Count                   8               4         12
   Expected count          7.2             4.8       12.0
   % within type of SSRI   66.7%           33.3%     100.0%
   Adjusted residual       .5              −.5        
  Paxil                                               
   Count                   17              12        29
   Expected count          17.3            11.7      29.0
   % within type of SSRI   58.6%           41.4%     100.0%
   Adjusted residual       −.1             .1         
  Zoloft                                              
   Count                   41              34        75
   Expected count          44.8            30.2      75.0
   % within type of SSRI   54.7%           45.3%     100.0%
   Adjusted residual       −1.0            1.0        
  Lexapro and Zoloft                                  
   Count                   2               3         5
   Expected count          3.0             2.0       5.0
   % within type of SSRI   40.0%           60.0%     100.0%
   Adjusted residual       −.9             .9         
  Lexapro and Prozac                                  
   Count                   2               0         2
   Expected count          1.2             .8        2.0
   % within type of SSRI   100.0%          0.0%      100.0%
   Adjusted residual       1.2             −1.2      
  Lexapro and Paxil                                   
   Count                   0               2         2
   Expected count          1.2             .8        2.0
   % within type of SSRI   0.0%            100.0%    100.0%
   Adjusted residual       −1.7            1.7        
  Celexa and Zoloft                                   
   Count                   2               0         2
   Expected count          1.2             .8        2.0
   % within type of SSRI   100.0%          0.0%      100.0%
   Adjusted residual       1.2             −1.2       
                                                     
  Total                                               
   Count                   280             189       469
   Expected count          280.0           189.0     469.0
   % within type of SSRI   59.7%           40.3%     100.0%

Bold highlights the highest adjusted residual.
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